Tysabri and PML: How Soon Can Symptoms Develop?

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Awareness to Specific Risk: The Legacy of Informed Decision-Making

If you or a loved one is taking Tysabri and wondering about the risk of progressive multifocal leukoencephalopathy (PML), understanding when symptoms might appear is crucial. The medical community has long recognized that certain therapies carry delayed risks, and this knowledge forms the foundation for how we approach patient monitoring today. This page provides a clear timeline of PML symptom onset and what to watch for.

Understanding Tysabri and Its Association with PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis in adults (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by reactivation of the John Cunningham virus (JCV). The United States Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency’s most stringent safety alert, stating that the drug “increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability” (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical trial data and postmarketing surveillance. PML is a demyelinating disease of the central nervous system that results from lytic infection of oligodendrocytes by JCV. Clinical presentation typically includes subacute onset of neurologic deficits such as hemiparesis, visual field defects, cognitive decline, ataxia, and speech disturbances. Diagnosis is confirmed by detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction (PCR) or by brain biopsy showing characteristic histopathologic changes. The condition is often rapidly progressive and can lead to permanent disability or death. The FDA boxed warning emphasizes that healthcare professionals should “monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML” and that “TYSABRI dosing should be withheld immediately at the first sign or symptom suggestive of PML” (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Mechanism of Action and Risk Factors for PML

The mechanistic pathway linking Tysabri to PML involves the drug’s mode of action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of lymphocytes, preventing their adhesion to endothelial cells and subsequent migration across the blood-brain barrier. This reduces inflammatory activity in the central nervous system, which is beneficial for controlling multiple sclerosis relapses. However, by impairing immune surveillance within the brain, Tysabri creates an environment permissive for JCV reactivation and uncontrolled replication. The FDA has identified three key risk factors for PML development in Tysabri-treated patients: “the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants” (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are seropositive for anti-JCV antibodies, have received Tysabri for more than two years, or have previously used immunosuppressive medications face the highest risk. Postmarketing adverse event reports submitted to the FDA Adverse Event Reporting System (FAERS) list fatigue, multiple sclerosis relapse, headache, and gait disturbance among the most frequently reported events associated with Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not specifically enumerate PML cases, the boxed warning and clinical literature confirm that PML is a recognized and serious adverse effect. The FDA also notes that Tysabri increases the risk of herpes encephalitis and meningitis, with onset ranging from a few months to several years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Statute of Limitations for Tysabri-Related PML Claims in Washington

For patients in Washington who have developed PML after Tysabri exposure, legal considerations regarding the statute of limitations are critical. The statute of limitations for personal injury claims in Washington is generally three years from the date the injury was discovered or reasonably should have been discovered. For PML, the timeline between Tysabri exposure and documented harm can be variable. The FDA notes that PML risk increases with duration of therapy, and cases have been reported after as few as a few months to several years of treatment. The latency period complicates the determination of when the injury was discoverable. Patients may not recognize early symptoms such as cognitive changes or motor deficits as PML, and diagnosis often requires specialized testing. The statute of limitations clock typically begins when the patient knows or has reason to know of both the injury and its potential link to Tysabri. Given the severity of PML, affected individuals and their families should seek prompt legal counsel to assess their specific circumstances. The adequacy of warnings regarding Tysabri and PML is a central issue in potential litigation. The FDA-mandated boxed warning is prominently displayed in the prescribing information, and the drug is only available through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This program requires that patients read a Medication Guide, understand the risks, and sign an enrollment form. Healthcare professionals must also be certified to prescribe and infuse Tysabri. Despite these measures, questions may arise about whether prescribers adequately communicated the risk of PML to patients, particularly in the context of evolving understanding of risk factors such as anti-JCV antibody status. Patients who were not informed of their anti-JCV antibody test results or who were not counseled about the cumulative risk over time may have grounds for claims based on inadequate warning.

Legal Considerations and Next Steps for Affected Individuals

Attorney-related considerations for affected patients include the need to preserve medical records documenting Tysabri administration dates, anti-JCV antibody test results, and the clinical course of PML diagnosis and treatment. Expert testimony from neurologists and infectious disease specialists may be required to establish causation and the standard of care. The timeline between exposure and harm is critical for both medical and legal purposes. Patients should document the date of first Tysabri infusion, the date of symptom onset, and the date of PML diagnosis. This information will help determine whether the claim falls within Washington’s statute of limitations and whether the drug manufacturer or prescribing physician may be liable for failure to warn or negligence. In summary, Tysabri carries a known and serious risk of PML, as reflected in its FDA boxed warning. The mechanistic link involves impaired immune surveillance in the brain due to the drug’s inhibition of lymphocyte migration. Patients in Washington who develop PML after Tysabri exposure face a limited window to pursue legal action, and the adequacy of warnings provided to them is a key factor in potential claims. Prompt consultation with an attorney experienced in pharmaceutical litigation is advisable to protect legal rights.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Washington?

In Washington, the statute of limitations for personal injury claims is generally three years from the date the injury was discovered or reasonably should have been discovered. For PML, the clock typically starts when the patient knows or has reason to know of both the injury and its potential link to Tysabri. Given the latency and diagnostic challenges, prompt legal consultation is crucial.

What are the key risk factors for developing PML while on Tysabri?

The FDA identifies three key risk factors: presence of anti-JCV antibodies, duration of therapy (especially over two years), and prior use of immunosuppressants. Patients with these factors face the highest risk of PML.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.